It is indicated for monotherapy of relapsing multiple sclerosis in adults, as well as induction and maintenance therapy of moderately to severely active Crohn's disease. Patients with Crohn's disease (CD) should not use it in combination with immunosuppressants or TNF-α inhibitors.

The injection is available in a concentration of 300mg/15mL (20mg/mL), presenting as a colorless to slightly opalescent solution, which requires dilution before intravenous infusion. The recommended dose is 300mg per administration, given intravenously once every 4 weeks, with the infusion time lasting approximately 1 hour. Intravenous push or rapid injection is strictly prohibited.